A compound of formula, or a pharmaceutically acceptable salt thereof, wherein: A is selected from a structure unit as shown in formula (A 1) or of formula (A 22): wherein: the structure unit is selected from phenyl; R 4 and R 6 are independently selected from H, F, Cl, Br, halogen-substituted or unsubstituted C 1-6 alkyl R 5 and R 7 are independently selected from optionally substituted 5-6 membered cyclohydrocarbyl or heterocyclic group, while the substituent is selected from F, Cl, Br, CN, halogen-substituted, or unsubstituted C 1-6 alkyl; wherein the 5-6 membered cyclohydrocarbyl or heterocyclic group are each independently selected from phenyl, pyridyl, furyl, thienyl, thiazolyl, pyrimidinyl, pyrazolyl, 1,2,3-triazolyl or 1,2,5-triazolyl; n 4 is selected from 0, 1, 2, 3, 4; n6a is selected from 0 or 1; and C1-6 alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, or hexyl; B is selected from C(=O); X is a single bond of linkage; D and L are CH 2 T is C; M is selected from C (R 1a) when Q is selected from C(R 1b)(R 1c), or M is selected from C(R 1b)(R 1c) when Q is selected from C (R 1a); Y is selected from CH 2 -O-E or -O-E or optionally substituted E is selected from a structure unit of formula (E a): wherein: the structure unit is defined as phenyl or pyridyl; R 8 and R 9 are independently selected from H, F, Cl, Br, halogen-substituted or unsubstituted C 1-6 alkyl; each of R 1a, R 1b, R 1c, R 2, and R 3 is independently selected from H, F, Cl, halogen-substituted or unsubstituted C 1-6 alkyl; and the compound or the pharmaceutically acceptable salt thereof comprises one or more chiral center. the structure unit is selected from phenyl; R 4 and R 6 are independently selected from H, F, Cl, Br, halogen-substituted or unsubstituted C 1-6 alkyl R 5 and R 7 are independently selected from optionally substituted 5-6 membered cyclohydrocarbyl or heterocyclic group, while the substituent is selected from F, Cl, Br, CN, halogen-substituted, or unsubstituted C 1-6 alkyl; wherein the 5-6 membered cyclohydrocarbyl or heterocyclic group are each independently selected from phenyl, pyridyl, furyl, thienyl, thiazolyl, pyrimidinyl, pyrazolyl, 1,2,3-triazolyl or 1,2,5-triazolyl; n 4 is selected from 0, 1, 2, 3, 4; n6a is selected from 0 or 1; and C1-6 alkyl is selected from methyl, ethyl, propyl, butyl, pentyl, or hexyl; B is selected from C(=O); X is a single bond of linkage; D and L are CH 2 T is C; M is selected from C (R 1a) when Q is selected from C(R 1b)(R 1c), or M is selected from C(R 1b)(R 1c) when Q is selected from C (R 1a); Y is selected from CH 2 -O-E or -O-E or optionally substituted E is selected from a structure unit of formula (E a): wherein: the structure unit is defined as phenyl or pyridyl; R 8 and R 9 are independently selected from H, F, Cl, Br, halogen-substituted or unsubstituted C 1-6 alkyl; each of R 1a, R 1b, R 1c, R 2, and R 3 is independently selected from H, F, Cl, halogen-substituted or unsubstituted C 1-6 alkyl; and the compound or the pharmaceutically acceptable salt thereof comprises one or more chiral center. the structure unit is defined as phenyl or pyridyl; R 8 and R 9 are independently selected from H, F, Cl, Br, halogen-substituted or unsubstituted C 1-6 alkyl; each of R 1a, R 1b, R 1c, R 2, and R 3 is independently selected from H, F, Cl, halogen-substituted or unsubstituted C 1-6 alkyl; and the compound or the pharmaceutically acceptable salt thereof comprises one or more chiral center.